Nectero Therapeutics – Nectero Therapeutics is developing a novel treatment to stabilize growth and prevent rupture of mid-sized abdominal aortic aneurysms (AAA).
Nectero Medical (now Nectero Therapeutics) is a clinical-stage biotech company developing the Nectero EAST® System, a minimally invasive endovascular procedure that delivers a stabilizing agent to strengthen the aortic wall and slow growth of small to medium-sized abdominal aortic aneurysms. The company received FDA Fast Track and Breakthrough Therapy designations in 2023 and raised a $94M Series D to advance its Phase II/III trial.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountApr 2024
Sep 2021
Create a free account to see which investors have funded this company.
Create Free Account
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...
Healthcare company applying technology to drug development by building nimble biotech subsidiarie...
Neuralink is building a brain-computer interface for medical needs and greater human potential.
